title: [Nicotinic acid increases cellular transport of high density lipoprotein cholesterol in patients with hypoalphalipoproteinemia].
abstract: BACKGROUND
  Plasma high density lipoproteins (HDL) are involved in reverse cholesterol transport mediated by the scavenger receptor class B type I (SR-BI). Nicotinic acid increases HDL cholesterol levels, even though its specific impact on SR-BI dependent-cellular cholesterol transport remains unknown.
  
  
  OBJECTIVE
  To determine the effect of nicotinic acid on HDL particle functionality in cholesterol efflux and uptake mediated by SR-BI in cultured cells in hypoalphalipoproteinemic patients.
  
  
  METHODS
  In a pilot study, eight patients with low HDL (≤ 40 mg/dL) were treated with extended release nicotinic acid. HDL cholesterol and phospholipid levels, HDL2 and HDL3 fractions and HDL particle sizes were measured at baseline and post-therapy. Before and after nicotinic acid treatment, HDL particles were used for cholesterol transport studies in cells transfected with SR-BI.
  
  
  RESULTS
  Nicotinic acid treatment raised total HDL cholesterol and phospholipids, HDL2 levels as well as HDL particle size. Nicotinic acid significantly increased HDL cholesterol efflux and uptake capacity mediated by SR-BI in cultured cells.
  
  
  CONCLUSIONS
  Nicotinic acid therapy increases SR-BI-dependent HDL cholesterol transport in cultured cells, establishing a new cellular mechanism by which this lipid-lowering drug appears to modulate HDL metabolism in patients with hypoalphalipoproteinemia.
authors.forename: Catalina
authors.initials: C
authors.lastname: Figueroa
authors.forename: Katherine
authors.initials: K
authors.lastname: Droppelmann
authors.forename: Verónica
authors.initials: V
authors.lastname: Quiñones
authors.forename: Ludwig
authors.initials: L
authors.lastname: Amigo
authors.forename: Camila
authors.initials: C
authors.lastname: Mendoza
authors.forename: Valentina
authors.initials: V
authors.lastname: Serrano
authors.forename: Margarita
authors.initials: M
authors.lastname: Véjar
authors.forename: Alberto
authors.initials: A
authors.lastname: Maiz
authors.forename: Attilio
authors.initials: A
authors.lastname: Rigotti
mesh_terms: D000368:Aged; D001692:Biological Transport; D008076:Cholesterol, HDL / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006801:Humans; D052456:Hypoalphalipoproteinemias / Q000378:metabolism*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008075:Lipoproteins, HDL / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000494:pharmacology*; D010743:Phospholipids / Q000097:blood; D010865:Pilot Projects; D051122:Scavenger Receptors, Class B / Q000378:metabolism
chemical_list: D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D010743:Phospholipids; C495124:SCARB1 protein, human; D051122:Scavenger Receptors, Class B; D009525:Niacin